2025
Overall Survival Prediction of Brain Tumor Patients with Multimodal MRI using Swin Unetr
Kim G, Xing F, Kong H, Santarnecchi E, Shih H, Bortfeld T, Fakhri G, Liu X, Choi J, Woo J. Overall Survival Prediction of Brain Tumor Patients with Multimodal MRI using Swin Unetr. 2025, 00: 1-5. DOI: 10.1109/isbi60581.2025.10981128.Peer-Reviewed Original ResearchMultimodal magnetic resonance imagingBrain tumor patientsGlioblastoma patient survivalPersonalized treatment plansSurvival prediction performanceMultimodal MRIOverall survival predictionMagnetic resonance imagingHand-crafted featuresState-of-the-artMulti-scale featuresMulti-task frameworkPatient survivalClinical prognosisTumor patientsGlioblastoma patientsSuperior segmentation accuracyTreatment planningResonance imagingSurvival prediction taskPredictive performanceSurvival predictionPrediction taskBRATS datasetSurvival
2023
EXTH-59. IDENTIFICATION OF GROWTH HORMONE RECEPTOR AS A RELEVANT TARGET FOR PRECISION MEDICINE IN LOW-EGFR EXPRESSING GLIOBLASTOMA
Verreault M, Vilchis I, Rosenberg S, Lemaire N, Schmitt C, Guehennec J, Royer-Perron L, Thomas J, Lam T, Dingli F, Loew D, Ducray F, Paris S, Carpentier C, Marie Y, Laigle-Donadey F, Rousseau A, Pigat N, Boutillon F, Bielle F, Mokhtari K, Frank S, de Reynies A, Hoang-Xuan K, Sanson M, Goffin V, Idbaih A. EXTH-59. IDENTIFICATION OF GROWTH HORMONE RECEPTOR AS A RELEVANT TARGET FOR PRECISION MEDICINE IN LOW-EGFR EXPRESSING GLIOBLASTOMA. Neuro-Oncology 2023, 25: v237-v237. PMCID: PMC10639947, DOI: 10.1093/neuonc/noad179.0912.Peer-Reviewed Original ResearchGrowth hormone receptorOncogenic mechanismsCommon oncogenic mechanismThird of patientsDistinct molecular subsetsNew therapeutic approachesPromising therapeutic targetHuman GBM samplesPatient-derived cell linesLower eGFRMolecular subsetsExpression of proteinsGBM patientsTherapeutic approachesGlioblastoma patientsTherapeutic targetTumor growthGrowth hormoneEGFR overexpressionPharmacological inhibitionSOCS2 expressionTumor invasionPatientsHormone receptorsGBM samples
2022
NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS
Moassefi M, Faghani S, Conte G, Rouzrokh P, Kowalchuk R, Trifiletti D, Erickson B. NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS. Neuro-Oncology Advances 2022, 4: i17-i18. PMCID: PMC9354212, DOI: 10.1093/noajnl/vdac078.069.Peer-Reviewed Original ResearchMagnetic resonance imagingGlioblastoma patientsMedian overall survival rangesTreatment planningOriginal radiation fieldOverall survival rangesStandard treatment regimenConventional magnetic resonance imagingT2-weighted imagesPatient treatment plansDiagnosing PSPAdjuvant temozolomideConcurrent chemoradiotherapySurgical resectionEnhancing lesionsAggressive tumorsMultimodal treatmentTreatment regimenAggressive managementRecurrence locationTrue progressionClinical historyClinical deteriorationMedical historyClinical challengeEfficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.Peer-Reviewed Original ResearchMedian overall survivalLaser interstitial thermal therapyOverall survivalRecurrent patientsWild-type glioblastomaRecurrent glioblastomaGlioblastoma patientsProspective multicenter registry dataMulticenter registry dataRecurrent glioblastoma patientsChemo/radiationPrimary brain tumorsInterstitial thermal therapyIDH wild-type glioblastomaAdjuvant chemotherapyAdverse eventsImproved survivalClinical outcomesPromoter methylation statusMultivariable differenceSurgical approachTreatment optionsRegistry dataUS CentersTumor volume
2021
Glioblastoma radiomics to predict survival: Diffusion characteristics of surrounding nonenhancing tissue to select patients for extensive resection
Pasquini L, Di Napoli A, Napolitano A, Lucignani M, Dellepiane F, Vidiri A, Villani V, Romano A, Bozzao A. Glioblastoma radiomics to predict survival: Diffusion characteristics of surrounding nonenhancing tissue to select patients for extensive resection. Journal Of Neuroimaging 2021, 31: 1192-1200. PMID: 34231927, DOI: 10.1111/jon.12903.Peer-Reviewed Original ResearchConceptsYear old patientSurvival stratificationOlder patientsRadiomic featuresExtent of resectionImprove patient selectionPrimary CNS neoplasmsCox regression modelsStandard of careLogistic regression analysisT-testNonenhancing tissueTumor resectionExtensive surgeryStandard therapyMRI pre-Patient selectionCNS neoplasmsGlioblastoma patientsMRI featuresRadiomics modelResectionEnhancing portionTreatment protocolsRisk factorsBRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort
Vassilakopoulou M, Won M, Curran WJ, Souhami L, Prados MD, Langer CJ, Rimm DL, Hanna JA, Neumeister VM, Melian E, Diaz AZ, Atkins JN, Komarnicky LT, Schultz CJ, Howard SP, Zhang P, Dicker AP, Knisely JPS. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. Oncology 2021, 99: 580-588. PMID: 33957633, PMCID: PMC8491475, DOI: 10.1159/000516168.Peer-Reviewed Original ResearchConceptsBRCA1 protein expressionTensin homolog (PTEN) tumor suppressor geneProtein expressionTumor suppressor geneQuantitative protein analysisDNA repairGenetic profiling studiesMolecular markersSuppressor geneProtein analysisProfiling studiesBRCA1 expressionSitu hybridizationExpression levelsTumor formationCommon malignant brain tumorCancer cellsTissue microarrayGlioblastoma tumorsExpressionPre-temozolomide eraGlioblastoma patients
2020
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, S A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.Peer-Reviewed Original ResearchConceptsProgrammed cell death protein 1Immunosuppressive tumor microenvironmentTumor-associated macrophagesTumor microenvironmentCD163+ tumor-associated macrophagesPD-1/PD-L1 immune checkpointCSF-1R inhibitor BLZ945Molecularly distinct GBM subtypesCell death protein 1Anti-PD-1 immunotherapyT cell functionNivolumab efficacyImmunotherapy efficacyImmune checkpointsImmune signaturesImmunosuppressive mechanismsT cellsM2-TAMsCo-administeredGlioblastoma patientsIL-10CSF-1RCSF-1ImmunotherapyProneural glioblastomaPenta-fluorophenol: a Smiles rearrangement-inspired cysteine-selective fluorescent probe for imaging of human glioblastoma
An J, Kang S, Huh E, Kim Y, Lee D, Jo H, Joung J, Kim V, Lee J, Dho Y, Jung Y, Hur J, Park C, Jung J, Huh Y, Ku J, Kim S, Chowdhury T, Park S, Kang J, Oh M, Park C, Kim D. Penta-fluorophenol: a Smiles rearrangement-inspired cysteine-selective fluorescent probe for imaging of human glioblastoma. Chemical Science 2020, 11: 5658-5668. PMID: 32874505, PMCID: PMC7449700, DOI: 10.1039/d0sc01085e.Peer-Reviewed Original ResearchLong-term toxicitySpecific diagnostic proceduresClinical biopsy samplesHuman-derived cellsImmune responseIndividual patientsMouse modelGlioblastoma patientsBiopsy samplesNew biomarkersClinical sitesDisease sitesHuman tissue samplesDiagnostic proceduresGBM cellsHuman glioblastomaTreatment progressTissue samplesClinical samplesCysteine levelsPatientsPrecision diagnosisPresent findingsGBMImaging
2019
Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays.
Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Shao Y, Karlin-Neumann G, Polsky D, Chi A. Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. Journal Of Clinical Oncology 2019, 37: 2026-2026. DOI: 10.1200/jco.2019.37.15_suppl.2026.Peer-Reviewed Original ResearchCell-free circulating tumor DNADroplet digital PCR assayDroplet digital PCRCtDNA levelsTERT mutationsPharmacodynamic biomarkersPlasma cell-free circulating tumor DNATERT promoter hotspot mutationsTERT promoter mutationsPromoter hotspot mutationsFFPE tumor samplesUnresected glioblastomaC228TPreoperative MRIIDH-wildtypeTumor DNADigital PCR assayIDHwt glioblastomasClinical stabilityTumor mutationsClinical outcomesClinical associationsGlioblastoma patientsHotspot mutationsTumor samplesOrgan‐on‐a‐Chip: Ex vivo Dynamics of Human Glioblastoma Cells in a Microvasculature‐on‐a‐Chip System Correlates with Tumor Heterogeneity and Subtypes (Adv. Sci. 8/2019)
Xiao Y, Kim D, Dura B, Zhang K, Yan R, Li H, Han E, Ip J, Zou P, Liu J, Chen A, Vortmeyer A, Zhou J, Fan R. Organ‐on‐a‐Chip: Ex vivo Dynamics of Human Glioblastoma Cells in a Microvasculature‐on‐a‐Chip System Correlates with Tumor Heterogeneity and Subtypes (Adv. Sci. 8/2019). Advanced Science 2019, 6: 1970046. PMCID: PMC6468959, DOI: 10.1002/advs.201970046.Peer-Reviewed Original ResearchLonger Median Overall Survival in Glioblastoma Patients from Racial and Ethnical Minority Groups (S30.007)
Yu S, Patel A, Crispino S, Utate M, Kurz S. Longer Median Overall Survival in Glioblastoma Patients from Racial and Ethnical Minority Groups (S30.007). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.s30.007.Peer-Reviewed Original Research
2018
HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL
Blondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.Peer-Reviewed Original ResearchQuality-adjusted life yearsHealth utility valuesLong-term survivorsLong-term survivalHealth utilityCondition-specific questionnaireEF-14 trialQuality of lifeHealth economic evaluationsGeneral population sampleStable diseaseAdverse eventsPreference-based measuresMultiple myelomaGBM patientsHealth state scenariosGlioblastoma patientsPatientsGBM treatmentSurvival rateLife yearsNew treatmentsUtility valuesDiagnosisHealth Panel
2017
PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE
Blondin N. PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE. Neuro-Oncology 2017, 19: vi169-vi169. PMCID: PMC5692009, DOI: 10.1093/neuonc/nox168.688.Peer-Reviewed Original ResearchMalignant glioma patientsCannabis treatmentGlioma patientsCannabis therapyInitial experienceTherapeutic useBeneficial palliative effectBrain tumor symptomsCertain medical conditionsLow usePalliative useStandard therapyTumor symptomsOral sprayTherapeutic roleMalignant gliomasPalliative effectMild fatigueAnaplastic astrocytomaMedical conditionsAstrocytoma casesGlioblastoma patientsPatientsSide effectsAnimal modelsRabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential
Altinoz M, Guloksuz S, Elmaci İ. Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential. Clinical And Translational Oncology 2017, 19: 785-792. PMID: 28093702, DOI: 10.1007/s12094-017-1613-6.Peer-Reviewed Original ResearchConceptsRabies virus vaccineImmune adjuvantsVirus vaccineGL261 mouse glioma modelNovel immune adjuvantsPilot clinical studyMouse glioma modelImmunotherapeutic modalitiesCervical cancerClinical studiesHealth StudyGlioblastoma patientsGlioma modelProtective roleLiterature searchCancerPublic health studiesRabies virusRemissionPatientsAdjuvantRelevant databasesRecent findingsInjectionKey words
2016
ACTR-10. PHASE 0 TRIAL OF AZD1775 IN FIRST-RECURRENCE GLIOBLASTOMA PATIENTS
Sanai N, Li J, Boerner J, Dhruv H, Berens M, LoRusso P. ACTR-10. PHASE 0 TRIAL OF AZD1775 IN FIRST-RECURRENCE GLIOBLASTOMA PATIENTS. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.009.Peer-Reviewed Original ResearchPhase 0 trialsInterindividual variabilityGlioblastoma patientsPhase II studyApparent oral clearanceGlomerular filtration ratePhase I trialCL/F.CL/FSparse blood samplingElimination rate constantAbsorption rate constantPD endpointsAdult patientsII studyOral clearanceI trialSingle doseDrug exposureFiltration ratePreclinical modelsPreclinical studiesGlioma patientsPlasma ratioBlood samplingHypoxic glucose metabolism in glioblastoma as a potential prognostic factor
Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, Terasaka S, Kobayashi H, Hattori N, Shiga T, Kuge Y, Tanaka S, Ito YM, Tamaki N. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 44: 611-619. PMID: 27752745, DOI: 10.1007/s00259-016-3541-z.Peer-Reviewed Original ResearchConceptsProgression-free survivalExtent of resectionStandardized uptake valuePositron emission tomographyGross tumor volumeFMISO positron emission tomographyMagnetic resonance imagingKarnofsky Performance ScaleOverall survivalTumor volumeGlioblastoma patientsHypoxia volumeFDG positron emission tomographyFluorodeoxyglucose positron emission tomographyPotential prognostic factorsTotal lesion glycolysisMetabolic tumor volumeHypoxic volumeVolume of interestGadolinium-enhanced T1-weighted MR imagesReference regionT1-weighted MR imagesCytoreduction surgeryFree survivalPrognostic factors
2015
GENO-21BRCA1 PROTEIN EXPRESSION PREDICTS SURVIVAL IN GLIOBLASTOMA PATIENTS FROM A NRG ONCOLOGY/RTOG COHORT
Vassilakopoulou M, Won M, Curran W, Souhami L, Prados M, Langer C, Rimm D, Hanna J, Neumeister V, Smart W, Diaz A, Atkins J, Komarnicky L, Schultz C, Howard S, Dicker A, Knisely J. GENO-21BRCA1 PROTEIN EXPRESSION PREDICTS SURVIVAL IN GLIOBLASTOMA PATIENTS FROM A NRG ONCOLOGY/RTOG COHORT. Neuro-Oncology 2015, 17: v96-v96. PMCID: PMC4638813, DOI: 10.1093/neuonc/nov215.21.Peer-Reviewed Original ResearchProspects of immune checkpoint modulators in the treatment of glioblastoma
Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology 2015, 11: 504-514. PMID: 26260659, PMCID: PMC4782584, DOI: 10.1038/nrneurol.2015.139.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsGlioblastoma patientsMultiple immunosuppressive mechanismsMedian overall survivalImmune checkpoint modulatorsBlood-brain barrierTreatment of glioblastomaOverall survivalImmunosuppressive mechanismsAdvanced tumorsClinical benefitImmunotherapeutic agentsConventional therapyCheckpoint modulatorsLung cancerImmune systemPatientsCancerInhibitorsCurrent understandingImmunotherapyPrognosisLymphocytesTherapypH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI
Harris R, Cloughesy T, Liau L, Prins R, Antonios J, Li D, Yong W, Pope W, Lai A, Nghiemphu P, Ellingson B. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology 2015, 17: 1514-1524. PMID: 26113557, PMCID: PMC4648305, DOI: 10.1093/neuonc/nov106.Peer-Reviewed Original ResearchConceptsAmine chemical exchange saturation transferPH-weighted MRIShorter time to progressionAcid lesionsTime to progressionChemical exchange saturation transfer MRIMolecular imaging of gliomaIntracranial glioma modelBrain tumor physiologyImaging of gliomasActive tumorAbnormal perfusionGlioma modelPerfusion abnormalitiesGlioblastoma patientsMolecular imaging techniquesPET uptakeTumor physiologyMR spectroscopyTissue acidosisChemical exchange saturation transferHuman patientsPatientsTumorLesionsTERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
Mosrati M, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck A, Bratthäll C, Strandéus M, Stenmark-Askmalm M, Söderkvist P. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015, 6: 16663-16673. PMID: 26143636, PMCID: PMC4599297, DOI: 10.18632/oncotarget.4389.Peer-Reviewed Original ResearchConceptsTERT promoter mutationsShorter overall survivalOverall survivalPromoter mutationsC228TInterleukin-6 expressionPrimary glioblastoma patientsTypes of tumorsReverse transcriptase activityPrognostic factorsShorter survivalIL-6GBM patientsTERT promoter statusGlioblastoma patientsHomozygous carriersC alleleTumours leadsC250TPrimary glioblastomaPromoter statusTERT promoterMinor alleleGlioblastomaTranscriptase activity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply